Reversibility is rarely free; understanding when to step outside the HA bracket is one of the higher-skill calls in injectable practice.
Hyaluronic acid (HA) fillers dominate aesthetic practice for good reason: they are familiar, titratable, and reversible. Yet a growing body of clinical evidence supports the structured use of non-HA agents in selected indications, particularly where collagen biostimulation, extended longevity, or resistance to enzymatic dissolution are the primary clinical objectives. This article provides a practical decision framework for licensed UK practitioners evaluating filler choice beyond the HA default.
For a full range of products to support your clinic, visit our dermal fillers collection or browse our complete product range.
The HA Filler: Clinical Strengths and Limitations
HA fillers remain the most widely used class of injectable filler in the UK. Cross-linked HA integrates with the extracellular matrix, providing immediate volume correction with a predictable safety profile. The principal advantage is enzymatic reversibility: hyaluronidase (the active enzyme used generically across all reversal products) degrades HA substrate rapidly, allowing practitioners to address vascular compromise or overcorrection within a controlled timeframe.
Guidance on hyaluronidase dosing and administration is well established in UK practice. The Journal of Clinical and Aesthetic Dermatology guideline on hyaluronidase use in aesthetics provides a structured protocol for reversal in both elective and emergency contexts (JCAD safe use of hyaluronidase). The same publisher has produced specific guidance on vascular occlusion management (JCAD CMAC vascular occlusion guideline).
The limitations of HA are equally well documented. Longevity is moderate: depending on cross-linking density, particle size, and the anatomical zone treated, most HA products require retreatment at 9 to 18 months. HA fillers also provide predominantly rheological volume rather than active tissue remodelling, making them a poor fit where the clinical objective is dermal thickening or neocollagenesis rather than structural fill.
Calcium Hydroxylapatite (CaHA): Mechanism and Indications
Calcium hydroxylapatite (CaHA), available in the UK as Radiesse (Merz, manufacturer product information), consists of CaHA microspheres suspended in an aqueous gel carrier. The carrier provides immediate volumising effect; over a period of three to four months the microspheres act as a scaffold for fibroblast recruitment and collagen deposition, as described in a review published in PubMed Central (PMC8570661).
CaHA is not reversible with hyaluronidase. The absence of HA substrate means enzymatic dissolution is not an option, and practitioners must rely on dilution techniques, aspiration, or time for product modification. This places a higher premium on precise placement and appropriate patient selection.
Clinically, CaHA performs well in the mid and lower face where structural support and skin quality improvement are concurrent objectives: the jawline, chin, cheeks, and the dorsum of the hands. Longevity of 12 to 18 months is routinely reported in the clinical literature, with biostimulatory effects persisting beyond product resorption (Merz, manufacturer product information).
Poly-L-Lactic Acid (PLLA): The Long-Game Biostimulator
Poly-L-lactic acid (PLLA), marketed as Sculptra (Galderma, manufacturer product information), operates differently from both HA and CaHA. It contains no immediate volumising carrier: results emerge gradually over three to four months as PLLA microparticles stimulate fibroblast activity and de novo collagen synthesis. Multiple treatment sessions are required, typically three sessions spaced four to six weeks apart, before optimal correction is visible.
The clinical benefit is the extended duration: peer-reviewed data support maintenance of correction for 24 months or longer in appropriate patients (Galderma, manufacturer product information). PLLA is therefore best suited to patients who accept a delayed onset in exchange for prolonged, natural-looking improvement, particularly in areas of global volume loss such as the temples, cheeks, and anterior face.
Like CaHA, PLLA is not reversible with hyaluronidase. Nodule formation, a recognised complication associated with sub-optimal reconstitution or injection into high-mobility zones, reinforces the importance of rigorous technique. Current guidance from the British College of Aesthetic Medicine covers filler safety standards relevant to all non-HA products (BCAM dermal fillers guidance).
Polycaprolactone (PCL): Longevity with Biostimulation
Polycaprolactone (PCL), available in the UK as Ellanse (Sinclair, manufacturer product information), is a bioresorbable synthetic polymer that combines an immediate volumising CMC gel carrier with a sustained biostimulatory scaffold. Unlike PLLA, Ellanse provides visible correction at the time of injection while the PCL microspheres degrade slowly, stimulating collagen production over 12 to 48 months depending on the product variant selected (Sinclair, manufacturer product information).
PCL occupies a distinctive niche for patients seeking both immediate gratification and extended duration without the multi-session commitment of PLLA. Indicative longevity ranges from one year (Ellanse-S) to four years (Ellanse-E), with the practitioner selecting the appropriate variant based on patient age, tissue quality, and treatment zone. As with CaHA and PLLA, PCL is not reversible with hyaluronidase.
Comparative Overview
| Filler Class | Example Product | Mechanism | Onset of Effect | Longevity | Reversible with Hyaluronidase | Ideal Indications |
|---|---|---|---|---|---|---|
| Hyaluronic acid (HA) | Multiple brands | Hydrophilic volume; extracellular matrix integration | Immediate | 9 to 18 months | Yes | Lips, nasolabial folds, tear troughs, acute volume correction, first-time patients |
| Calcium hydroxylapatite (CaHA) | Radiesse (Merz) | Gel carrier provides immediate volume; CaHA microspheres scaffold neocollagenesis | Immediate (volume); 3 to 4 months (biostimulatory) | 12 to 18 months | No | Mid-face structure, jawline, chin, hands |
| Poly-L-lactic acid (PLLA) | Sculptra (Galderma) | Microparticle-driven fibroblast activation; de novo collagen synthesis | Gradual (3 to 4 months post-final session) | 24 months or more | No | Global facial volume loss, temples, cheeks; patients accepting delayed onset |
| Polycaprolactone (PCL) | Ellanse (Sinclair) | CMC gel carrier for immediate volume; PCL microspheres for sustained collagen stimulation | Immediate (volume); ongoing (biostimulatory) | 12 to 48 months (variant-dependent) | No | Mid-face, jawline; patients wanting single-session correction with extended duration |
The Reversibility Question: When It Overrides Everything Else
Reversibility with hyaluronidase is not merely a convenience feature. In the context of vascular occlusion, it is a safety-critical property. The JCAD CMAC guideline on managing vascular occlusion from HA fillers sets out the expectation that practitioners administering HA fillers hold hyaluronidase on-site and can deploy it immediately (JCAD CMAC vascular occlusion guideline).
When a practitioner elects to use a non-HA filler, this safety net is absent. The clinical consequence is that pre-procedural vascular risk assessment must be more rigorous, cannula technique should be considered where anatomy supports it, and aspiration protocols take on greater significance. Non-HA fillers should not be used in high-risk zones such as the glabella, nasal tip, or periorbital region by practitioners who are not confident in advanced anatomy and emergency management of vascular events without enzymatic reversal.
This does not make non-HA fillers inherently more dangerous. It makes patient and zone selection more determinative of safety outcome than filler class alone.
A Practical Decision Framework
The following questions provide a clinical checklist for filler class selection:
- Is reversibility a hard requirement? First-time patients, high-risk anatomical zones, and any case where asymmetry risk is high should default to HA until the practitioner has confidence in the result. If yes, use HA.
- Is the primary objective volume or tissue quality? Where dermal thickening, skin laxity improvement, and structural scaffold matter more than acute volume correction, biostimulatory agents (CaHA, PLLA, PCL) are better matched to the objective.
- What longevity does the patient require and accept? HA suits patients who prefer flexibility. CaHA suits those who want moderate duration with moderate biostimulation. PLLA suits those accepting a multi-session protocol for the longest clinical effect. PCL suits those who want immediate correction plus extended duration in a single appointment.
- Is the patient prepared for a gradual result? PLLA requires explicit consent for delayed onset. Patients expecting immediate gratification equivalent to HA are not appropriate PLLA candidates.
- What is the zone being treated? High-mobility zones (lips, perioral), high-risk vascular zones (glabella, nose), and delicate zones (tear troughs) generally favour HA. Mid-face structure, jawline, temples, and hands are where non-HA agents are well evidenced.
- Does the patient have a history of autoimmune or inflammatory conditions? PLLA and PCL should be used with caution in patients with a history of granulomatous disease. CaHA is contraindicated in areas with known prior PLLA treatment due to nodule risk.
Practitioners looking to expand their injectable repertoire can browse our PDO threads collection alongside our dermal filler range for comprehensive tissue remodelling options.
Key Takeaways
- HA fillers remain the first-line choice in most indications due to enzymatic reversibility and a well-established safety profile.
- Non-HA biostimulatory fillers (CaHA, PLLA, PCL) provide collagen induction that HA cannot replicate, with longevity that extends to 24 to 48 months in selected agents.
- None of the non-HA agents reviewed are reversible with hyaluronidase. Patient selection, zone selection, and technique discipline replace enzymatic reversal as the primary safety controls.
- PLLA requires multi-session protocols and patient acceptance of delayed onset; it is not a like-for-like substitute for single-session HA treatment.
- PCL (Ellanse) is the only agent in this review that combines immediate volumising effect with a multi-year biostimulatory duration in a single session.
- Vascular risk assessment and emergency preparedness protocols must be adapted when working with non-HA agents, particularly in anatomically complex zones.
- All filler selection decisions should be made within a consented, documented treatment plan that reflects the individual patient's anatomy, objectives, and medical history.
References
- Journal of Clinical and Aesthetic Dermatology: Guideline for the safe use of hyaluronidase in aesthetic practice
- PubMed Central PMC8570661: Collagen biostimulation with calcium hydroxylapatite
- JCAD CMAC Guideline: Managing vascular occlusion following hyaluronic acid filler injection
- British College of Aesthetic Medicine: Dermal fillers guidance
- Merz Aesthetics: Radiesse manufacturer product information (Merz Pharmaceuticals GmbH)
- Galderma: Sculptra manufacturer product information (Galderma UK Ltd)
- Sinclair Pharma: Ellanse manufacturer product information (Sinclair Pharma)
Reviewed for clinical accuracy under the supervision of our Superintendent Pharmacist, Alicia Barker (GPhC 2241860). Longeva Pharmacy is a GPhC-registered pharmacy (registration 9012378) operating under MHRA WDA(H) licence 59619. Information is intended for licensed UK practitioners and does not replace individual clinical judgement.